Abstract:Interactions between pro- and anti-apoptotic Bcl-2 proteins decide the fate of the cell. The BH3 domain of pro-apoptotic Bcl-2 proteins interacts with the exposed hydrophobic groove of their anti-apoptotic counterparts. Through their design and development, BH3 mimetics that target the hydrophobic groove of specific anti-apoptotic Bcl-2 proteins have the potential to become anticancer drugs. We have developed a novel computational method for designing sequences with BH3 domain features that can bind specifically to anti-apoptotic Mcl-1 or Bcl-XL. In this method, we retained the four highly conserved hydrophobic and aspartic residues of wild-type BH3 sequences and randomly substituted all other positions to generate a large number of BH3-like sequences. We modeled 20000 complex structures with Mcl-1 or Bcl-XL using the BH3-like sequences derived from five wild-type pro-apoptotic BH3 peptides. Peptide-protein interaction energies calculated from these models for each set of BH3-like sequences resulted in negatively skewed extreme value distributions. The selected BH3-like sequences from the extreme negative tail regions have highly favorable interaction energies with Mcl-1 or Bcl-XL. They are enriched in acidic and basic residues when they bind to Mcl-1 and Bcl-XL, respectively. With the charged residues often away from the binding interface, the overall electric field generated by the charged residues results in strong long-range electrostatic interaction energies between the peptide and the protein giving rise to high specificity. Cell viability studies of representative BH3-like peptides further validated the predicted specificity. This study has revealed the importance of non-hot spot residues in BH3-mimetic peptides in providing specificity to a particular anti-apoptotic protein.

An Anthraquinone Scaffold for Putative, Two-Face Bim BH3 Α-Helix Mimic.

Two‐Face, Two‐Turn Α‐helix Mimetics Based on a Cross‐Acridine Scaffold: Analogues of the Bim BH3 Domain

Design and application of a rigid quinazolone scaffold based on two-face Bim α-helix mimicking.

Novel Mcl-1/Bcl-2 dual inhibitors created by the structure-based hybridization of drug-divided building blocks and a fragment deconstructed from a known two-face BH3 mimetic.

Terphenyl-Based Bak Bh3 Alpha-Helical Proteomimetics As Low-Molecular-Weight Antagonists Of Bcl-X-L

Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like Α-Helical Mimetics.

Development of XIAP Antagonists Based on De Novo 8,5-Fused Bicyclic Lactams.

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Design and Application of an Α‐helix‐mimetic Scaffold Based on an Oligoamide‐Foldamer Strategy: Antagonism of the Bak BH3/Bcl‐xL Complex

Computational Design of BH3-Mimetic Peptide Inhibitors That Can Bind Specifically to Mcl-1 or Bcl-XL: Role of Non-Hot Spot Residues

ChemInform Abstract: Probing the Difference Between BH3 Groove of Mcl‐1 and Bcl‐2 Protein: Implications for Dual Inhibitors Design.

Synthesis and Helical Structure of Lactam Bridged BH3 Peptides Derived from Pro-Apoptotic Bcl-2 Family Proteins

Terephthalamide Derivatives As Mimetics Of The Helical Region Of Bak Peptide Target Bcl-Xl Protein

Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry.

A Conserved Hydrophobic Core At Bcl-X(L) Mediates Its Structural Stability And Binding Affinity With Bh3-Domain Peptide Of Pro-Apoptotic Protein

Terephthalamide Derivatives As Mimetics of Helical Peptides: Disruption of the Bcl-x(L)/Bak Interaction.

Development of a Potent Bcl-xLAntagonist Based on Α-Helix Mimicry

Structure–activity Based Study of the Smac-binding Pocket Within the BIR3 Domain of XIAP

Binding of Anti-Apoptotic Bcl-2 with Different BH3 Peptides: A Molecular Dynamics Study

Structure‐based Design, Synthesis, and Evaluation of Bcl‐2/Mcl‐1 Dual Inhibitors

Design, synthesis of symmetrical bivalent mimetics of annonaceous acetogenins and their cytotoxicities.